• Jean-Christophe Lagier, Sophie Amrane, Morgane Mailhe, Marc Gainnier, Sylvie Arlotto, Stéphanie Gentile, and Didier Raoult.
• Aix-Marseille Université, IRD, MEPHI, APHM, IHU Méditerranée Infection, Marseille, France.
• Int. J. Infect. Dis. 2021 Apr 3; 108: 1-3.

ObjectivesIn a conventional hospital ward, we used high-flow nasal oxygen (HFNO) to treat elderly COVID-19 patients noneligible for intensive care unit transfer.MethodsThis study was conducted in the Institut Hospitalo-Universitaire Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille (AP-HM), France. We used high-flow nasal oxygen (HFNO) in our conventional infectious disease ward from 15 September 2020 for elderly patients noneligible for intensive care unit transfer.ResultsOf the 44 patients (median age 83 years (57-94), mean: 80.25), 61.4% (27/44) were men. The median Charlson score was 7 (1-15). The median of the NEWS-2 score upon admission was 8 (3-11) and was 10 at the time of initiation of HFNO. The median PaO2/FiO2 ratio was 103 (71-151) prior to HNFO initiation. Among the 44 patients, 16 patients (36.4%) had been weaned from HFNO, and 28 patients had died (63.6%).ConclusionsIn this preliminary report, we observed that HFNO saved the lives of one-third of elderly COVID-19 patients who would have systematically died.Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

4 keywords...

hide…